ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– Redox, the company making healthcare data useful, today announced it has raised $45m in Series D funding.
– The round was led by global private equity firm Adams Street Partners, with participation from Avenir and existing investors Battery Ventures, .406 Ventures, and RRE Ventures.
– This funding was preceded by a consistent pattern of acceleration. With integrations booming by 300% and the company surpassing 1,000 live connections on the Redox network in October 2020, Redox continues on an exponential trajectory.